Loading the records…
Loading the records…
HR10919, introduced on October 29, 2026, seeks to amend the 340B Drug Pricing Program to ensure safety net providers pay no more than the ceiling price at purchase. The bill is in early stage, referred to the House Energy and Commerce Committee. Its market impact is currently low and uncertain, pending further legislative action.
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
The bill is too early in the process to have measurable market implications. If it advances, drug manufacturers with significant 340B exposure could face modest pricing constraints, but the impact would likely be small relative to their overall revenues. No real market data is available to assess current pricing trends related to this bill.
The bill was introduced by Rep. Bergman (R-MI) with 13 bipartisan cosponsors. It would amend the Public Health Service Act to require that covered outpatient drugs be sold to 340B covered entities at or below the statutory ceiling price at the time of purchase. This addresses concerns that some providers may be charged above the ceiling price, particularly in contract pharmacy arrangements. The bill is at the beginning of the legislative process; it must pass committee, the House, the Senate, and be signed by the President to become law. No funding is authorized. The primary impact would be on drug manufacturers and pharmacy benefit managers, but the magnitude is unclear. Given the early stage, no specific companies can be identified with high confidence as winners or losers. Investors should monitor committee markup for amendments that could clarify the scope.
Matched on shared policy language across AI analyses, with ticker & timing weight
To amend title XXVII of the Public Health Service Act to ensure the equitable treatment of covered entities and pharmacies participating in the 340B drug discount program, and for other purposes.
Community Health Center Drug Pricing Protection Act
Executive orders & memoranda affecting the same sectors or companies
This executive order establishes a Women's Health Division within the NIH to coordinate and accelerate research on understudied women's health conditions, and creates a White House Women's Health Task Force to drive policy reforms and translation of research into clinical practice across federal agencies. It directs specific agencies to prioritize research, data collection, and translation into prevention, diagnosis, and treatment, with a focus on all life stages from infancy through aging.
This executive order directs the Secretaries of State, Labor, and Homeland Security to coordinate with Commerce, Education, and the SBA when processing H-1B petitions, and requires them to consider whether the employer has engaged in layoffs of similarly situated U.S. workers within the past year. It also orders the Labor Department to review past labor condition applications for potential enforcement actions against sponsoring employers, effectively tightening scrutiny on H-1B usage, especially by outsourcing firms.
This proclamation orders the Secretaries of War and Veterans Affairs to mandate rapid, ongoing digital sharing of military personnel and medical records, deploy AI-powered tools for benefits applications, and update existing IT contracts for interoperability. It also requires the Transition Assistance Program to connect separating service members to specific jobs or training programs before discharge.
Free — no credit card
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →